Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf CAR-NK Cell Therapies to Treat Solid Tumors
Catamaran Bio, Inc. , a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, today announced that the company has launched with $42 million in financing.
- Catamaran Bio, Inc. , a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, today announced that the company has launched with $42 million in financing.
- To date, the success of autologous CAR T-cell therapies in hematological malignancies has opened the door to the breakthrough potential of cell therapies for cancer, and Catamaran is now well positioned to improve upon this groundwork by developing off-the-shelf CAR-NK cell therapies capable of reaching solid tumors.
- Catamaran is focused on expanding the frontier of cell therapies to treat solid tumors and provide transformative benefit to cancer patients.
- Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors.